BAN1503 / BioArctic - LARVOL DELTA

BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects (FierceBiotech) - "Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million upfront for global rights to two preclinical antibodies. BioArctic is partnered with Eisai on multiple Alzheimer’s molecules, including Leqembi, but has switched its allegiance for the next two prospects to rattle down its pipeline. BMS secured rights to the two drug candidates, BAN1503 and BAN2803, in return for the upfront fee and up to $1.25 billion in development, regulatory and commercial milestones."

Licensing / partnership • Alzheimer's Disease • CNS Disorders